Juliette Tennenbaum

Juliette Tennenbaum

Auto-generated profile, based on publicly available information

Juliette Tennenbaum

French National Reference Center for sickle cell disease, thalassaemia and other red blood cell and erythropoiesis disorders, Department of Internal Medicine European Georges Pompidou Hospital, Assistance Publique – Hôpitaux de Paris (AP‐HP), Paris‐Cité University Paris Paris France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
JTJuliette Tennenbaum
Juliette Tennenbaum
MGMatthieu Groh
Matthieu Groh
LVLaura Venditti
Laura Venditti
FCFrance Campos-Gazeau
France Campos-Gazeau
ECEmilie Chalayer
Emilie Chalayer
JRJulien Rohmer
Julien Rohmer
Background and Purpose: Ischemic stroke has been reported in various conditions associated with eosinophilia. FIP1L1-PDGFRA fusion ([Fip1-like 1-platelet-derived growth factor receptor alpha]; F/P ) leads to the proliferation of the eosinophilic lineage and thus to a clonal hypereosinophilic syndrome that is highly responsive to imatinib. Methods: We previously reported on a nationwide retrospective study of 151 patients with F/P -associated clonal hypereosinophilic syndrome. Patients from this cohort with a clinical history of ischemic stroke (as well as 2 additional cases) were further analyzed to better define their clinical picture and outcomes. Results: Sixteen male patients (median age, 51 [43–59] years) with low-to-intermediate cardiovascular risk were included. Median National Institutes of Health Stroke Scale was 4 (range, 1–6). Most cerebral imaging disclosed multiple bilateral infarctions of watershed distribution (69%). Despite frequent cardiac involvement (50%), cardiac thrombus was evidenced in a single patient and, according to the TOAST classification (Trial of ORG 10172 in Acute Stroke Treatment), 62.5% of strokes were presumably of undetermined etiology. Among the 15 patients treated with imatinib, and after a median follow-up of 4.5 years, stroke recurred in only 3 patients (consisting of either cardio embolic or hemorrhagic events, unrelated to the first episode). Conclusions: F/P + clonal hypereosinophilic syndrome is a diagnosis to consider in patients with unexplained ischemic stroke and hypereosinophilia (especially in the setting of multiple cortical borderzone distribution) and warrants prompt initiation of imatinib.

14 March 2023 in British Journal of Haematology
Verified
Journal Article
Closed access
JTJuliette Tennenbaum
Juliette Tennenbaum
GVGeoffroy Volle
Geoffroy Volle
JPJacques Pouchot
Jacques Pouchot
LJLaure Joseph
Laure Joseph
DKDjamal Khimoud
Djamal Khimoud
JAJean‐Benoît Arlet
Jean‐Benoît Arlet

27 January 2023 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
JTJ. Tennenbaum
J. Tennenbaum
GVG. Volle
G. Volle
PBP. Buffet
P. Buffet
BRBrigitte Ranque
Brigitte Ranque
JPJACQUES POUCHOT
JACQUES POUCHOT
JAJ.-B. Arlet
J.-B. Arlet